Lejárt a biztonsági időkorlát.
Ha az oldal űrlapot is tartalmaz, annak mentése csak érvényes bejelentkezéssel lehetséges.
A bejelentkezés érvényességének meghosszabbításához kérjük lépjen be!
Felhasználó név:
Jelszó:
 

Féléves folyóirat
az SM betegek mindennapi életének javítására



Postacím: 1386 Budapest,
Pf. 906/97 „SMs üzenet”


Telefon: 06-80-630-660

Sms szám: 06-309-630-660

Legfrissebb kongresszusok

    A közeljövőben nincs rendezvényünk.
    Legutóbbi rendezvényünk
  • AAN 68th Annual Meeting

    2016.04.16.
    Vancouver, BC, Canada

További rendezvények
6. Irodalom

  1. ABN guidelines for treatment of multiple sclerosis with b-interferon and glatiramer acetate. 2007.
  2. American Academy of Neurology. The Role of Corticosteroids in the Management of Acute Monosymptomatic Optic Neuritis. 2000. URL: http://www.aan.com.
  3. American Academy of Neurology. The Usefulness of Evoked Potentials in Identifying Clinically Silent Lesions in Patients with Suspected Multiple Sclerosis. 2000. URL: http://www.aan.com.
  4. American Academy of Neurology. Disease Modifying Therapies in Multiple Sclerosis. 2002. URL: http://www.aan.com.
  5. American Academy of Neurology. Immunization and Multiple Sclerosis: A Summary of Published Evidence and Recommendations. Utility of MRI in Suspected MS. 2002. URL: http://www.aan.com.
  6. American Academy of Neurology. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. 2003. URL: http://www.aan.com.
  7. American Academy of Neurology. Utility of MRI in Suspected MS. 2003. URL: http://www.aan.com.
  8. Andersson M, Alvarez Cermeno J, Bernadi G. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994;57:897–902.
  9. Barkhof F, Polman CH, Radue EW et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol. 2007;64:1292–1298.
  10. Beck RW, Cleary PA, Anderson Jr MM, et al. A randomised controlled trial of corticosteroids in the treatment of acute optic neuritis: the Optic Neuritis Study Group. N Engl J Med. 1992;326:581–588.
  11. Bencsik K, Rajda C, Füvesi J et al. The prevalence of multiple sclerosis, distribution of clinical forms of the disease and functional status of patients in Csongrad county, Hungary. Eur Neurol. 2001;46:206–209.
  12. Bencsik K, Rajda C, Klivényi P, et. al. The prevalence of multiple sclerosis in the Hungarian city of Szeged. Acta Neurologica Scandinavica. 1998;97:315–319.
  13. Boster A, Edan G, Frohman E et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 2008;7:173–183.
  14. Boz C, Oger J, Gibbs E, Grossberg SE; Neurologists of the UBC MS Clinic. Reduced effectiveness of long-term interferonbeta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinicbased study. Mult Scler. 2007;13:1127–1137.
  15. Brainin M, Barnes M, Baron JC, Gilhus NE, Hughes R, Selmaj K, Waldemar G; Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces–revised recommendations. Eur J Neurol. 2004;11:577–581.
  16. Bowling AC, Stewart TM. Dietary supplements and multiple sclerosis. A health professional’s guide. Demos Medical Publishing, New York, 2004.
  17. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon Treatment On conversion to definite Multiple sclerosis (ETOMS): a randomized study. Lancet. 2001;357:1576–1582.
  18. Coyle PK. Switching algorithms: from one immunomodulatory agent to another. J Neurol. 2008;255(Suppl 1):44–50.
  19. Csépány T. Sclerosis multiplex. In: Bánki MC, Bereczki D. Hatóanyagok – készítmények – terápia. Fókuszban a neurológia és a pszichiátria. Melinda Kiadó, Budapest, 2006, 41–56.
  20. Csépány T, Bereczki D. Immunmoduláns kezelés sclerosis multiplexben. Ideggyógyászati Szemle. 2004;57:401–416.
  21. Csépány T, Illés Zs. Sclerosis multiplex. In: Csépány T, Illés Zs. Klinikai neuroimmunológia. Matyus-Benten kiadó, 2005, 51–142.
  22. Devonshire V, Duquette P, Dwosh E, et al. The Immune system and hormones: review and relevance to pregnancy and contraception in women with MS. International MS Journal. 2003;10:45–50.
  23. Dwosh E, Guimond C, Duquette P, et al. The interaction of MS and pregnancy: a critical review. International MS Journal. 2003;10:39–42.
  24. European Study Group on interferon b-1b in secondary progressive MS. Placebo-controlled multicenter randomized trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1490–1497.
  25. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000;(4):CD001331.
  26. Goodin DS, Cohen BA, O’Connor P et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;71:766–773.
  27. Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology. 2002;58:169–178.
  28. Goodin DS, Frohman EM, Hurwitz B et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007;68:977–984.
  29. Hartung HP, Gonsette R, König N, et al. and the Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebocontrolled, double-blind, randomized, multicenter trial. Lancet. 2002;360:2018–2025.
  30. http://www.aan.com/professionals/practice/index.cfm.
  31. http://www.medical-tribune.hu.
  32. http://www.nationalmssociety.org/sourcebook-early.asp.
  33. http://www.update-software.com/publications/cochrane/.
  34. IFNB Multiple sclerosis study group, University of British Columbia MS/MRI analysis group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277–1285.
  35. IFNB Multiple sclerosis study group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology. 1993;43:655–661.
  36. Illés Zs. Az immunmodulációs terápiák. In: Illés Zs. Sclerosis multiplex és autoimmunitás az ezredfordulón. PTE Neurológiai Klinika kiadó, 2003, 205–268.
  37. Jacobs LD, Beck RW, Simon JG, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898–904.
  38. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-la for disease progression in relapsing-remitting multiple sclerosis. Ann Neurol. 1996;39:285–294.
  39. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III. multicenter, doubleblind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268–1276.
  40. Johnson KP, Brooks BR, Ford CC, et al. and the Copolymer 1 Multiple Sclerosis Study Group. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler. 2000;6:255–266.
  41. Kappos L, Freedman MS, Polman CH et al BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389–397.
  42. Kappos L, Polman C, Freedman MS et al on behalf of the BENEFIT Study Group. Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) clinical results. Mult Scler. 2005;11(Suppl 1):S10.
  43. Kleinschmidt-DeMasters BK, Tyler KL. Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis N Engl J Med. 2005;353:369–374.
  44. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.
  45. La Mantia L, Milanese C, Mascoli N, D’Amico R, Weinstock- Guttman B. Cyclophosphamide for multiple sclerosis (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  46. Langer-Gould A, Atlas S. Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab. N Engl J Med. 2005;353:375–381.
  47. Lovas G, Szilágyi N, Majtényi K et al. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain. 2000;123:308–317.
  48. Lublin FD, Reingold SC, for the National Multiple Sclerosis Society (USA). Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907–911.
  49. Lucchinetti CF, Bruck W, Rodriquez M et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathology. 1996;6:259–274.
  50. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121–127.
  51. Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis–new aspects and practical application. J Neurol. 2004;251:1329–39. Review.
  52. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  53. National Institute for clinical excellence (NHS). Multiple sclerosis. Management of multiple sclerosis in primary and secondary care. Clinical guideline 8. November 2003.
  54. National Multiple Sclerosis Society. Disease Management Consensus statement.
  55. Pálffy G. A sclerosis multiplex prevalenciája Pécsett. Ideggyógyászati Szemle. 1983;36:12–17.
  56. Paty DW, Li DK, the UBC MS/MRI Study Group and the INFB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662–667.
  57. Polman CH, O’Connor PW, Havrdova E, et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.
  58. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revision to the „McDonald criteria.” Ann Neurol. 2005;58:840–846.
  59. PRIMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized, double-blind placebo-controlled study of interferon b-1a in relapsing-remitting multiple sclerosis. Lancet. 1998;352:1498–1504.
  60. Rajda C, Bencsik K, Vécsei L; Magyarországi Sclerosis Multiplex Centrumok Orvosi Tanácsadó Testület tagjai. A natalizumab alkalmazása sclerosis multiplexben. Ideggyogy Sz. 2008;61:204–208.
  61. Rice G PA, Incorvaia B, Munari L, Ebers G, Polman C, D’Amico R, Filippini G. Interferon in relapsing-remitting multiple sclerosis (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  62. Rudick RA, Stuart WH, Calabresi PA et al. SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911–923.
  63. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  64. Soerensen PS, Deisenhammer F, Duda P, et al. For the EFNS Task Force on Anti-IFN-b Antibodies in Multiple Sclerosis: Guidelines on use of anti-IFN-b antibody measurements in multiple sclerosis: report of an EFNS Task Force on Anti-IFN-b Antibodies in Multiple Sclerosis. Eur J Neurology. 2005;12:817–827.
  65. Taus C, Solari A, D’Amico R, Branas P, Hyde C, Giuliani G, Pucci E. Amantadine for fatigue in multiple sclerosis (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  66. The PRISMS (Prevention of Relapses and Disability by Interferon b-la Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group. PRIMS-4: Long-term efficacy of interferon b-la in relapsing MS. Neurology. 2001;56:1628–1636.
  67. Thompson AJ, Montalban X, Barkhof F et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol. 2000;47:831–835.
  68. Van Assche G, Van Ranst M, Sciot R et al. Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn’s Disease. N Engl J Med. 2005;353:362–368.
  69. Vécsei L, Komoly S (szerk.). Sclerosis multiplex. Therapia kiadó, 2003.
  70. Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation for progressive multifocal leukoencephalopathy in patients treated with natalizumab. N Engl J Med. 2006;355:924–933.